Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

about

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

P2860

Q47281377-EA3FBAF2-CC54-4D35-8658-810783AD7B59 Q59136620-49CF25C3-401F-46D3-A598-CCFF4B721EBC

P2860

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Item

http://www.wikidata.org/entity/Q46095028

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@en

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@nl

type

Item

label

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@en

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@nl

prefLabel

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@en

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@nl

P1476

Niclosamide and Bicalutamide C ...... ide-Resistant Prostate Cancer.

@en

P2093

Alan P Lombard

http://www.w3.org/2001/XMLSchema#string

Allen C Gao

http://www.w3.org/2001/XMLSchema#string

Cameron M Armstrong

http://www.w3.org/2001/XMLSchema#string

Chengfei Liu

http://www.w3.org/2001/XMLSchema#string

Chong-Xian Pan

http://www.w3.org/2001/XMLSchema#string

Christopher P Evans

http://www.w3.org/2001/XMLSchema#string

Joy C Yang

http://www.w3.org/2001/XMLSchema#string

Nagalakshmi Nadiminty

http://www.w3.org/2001/XMLSchema#string

Vito Cucchiara

http://www.w3.org/2001/XMLSchema#string

Wei Lou

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Overcoming mutation-based resistance to antiandrogens with rational drug design

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.

P304

1521-1530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-16-0912

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28500234

http://www.w3.org/2001/XMLSchema#string

P932

5544572

http://www.w3.org/2001/XMLSchema#string

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

about

P2860

P2860

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932